GB201216017D0 - Inhibitor compounds - Google Patents

Inhibitor compounds

Info

Publication number
GB201216017D0
GB201216017D0 GBGB1216017.2A GB201216017A GB201216017D0 GB 201216017 D0 GB201216017 D0 GB 201216017D0 GB 201216017 A GB201216017 A GB 201216017A GB 201216017 D0 GB201216017 D0 GB 201216017D0
Authority
GB
United Kingdom
Prior art keywords
inhibitor compounds
inhibitor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1216017.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Priority to GBGB1216017.2A priority Critical patent/GB201216017D0/en
Publication of GB201216017D0 publication Critical patent/GB201216017D0/en
Priority to BR112015004489-1A priority patent/BR112015004489B1/pt
Priority to US14/426,549 priority patent/US9409907B2/en
Priority to ES17192253T priority patent/ES2742442T3/es
Priority to NO13760106A priority patent/NO2892889T3/no
Priority to EP13760106.8A priority patent/EP2892889B1/en
Priority to JP2015530495A priority patent/JP6216791B2/ja
Priority to HK15112642.0A priority patent/HK1211921B/en
Priority to PCT/GB2013/052360 priority patent/WO2014037750A1/en
Priority to PT137601068T priority patent/PT2892889T/pt
Priority to HUE13760106A priority patent/HUE036259T2/hu
Priority to ES13760106.8T priority patent/ES2655194T3/es
Priority to CN201380057967.7A priority patent/CN104837829B/zh
Priority to SI201330829T priority patent/SI2892889T1/sl
Priority to SM20170596T priority patent/SMT201700596T1/it
Priority to DK13760106.8T priority patent/DK2892889T3/en
Priority to DK17192253.7T priority patent/DK3293183T3/da
Priority to RU2015112580A priority patent/RU2673079C2/ru
Priority to RS20171314A priority patent/RS56750B1/sr
Priority to CA2884006A priority patent/CA2884006C/en
Priority to AU2013311434A priority patent/AU2013311434B2/en
Priority to HRP20171835TT priority patent/HRP20171835T1/hr
Priority to LTEP13760106.8T priority patent/LT2892889T/lt
Priority to EP17192253.7A priority patent/EP3293183B1/en
Priority to PL13760106T priority patent/PL2892889T3/pl
Priority to US15/091,980 priority patent/US9834552B2/en
Priority to US15/091,887 priority patent/US9890157B2/en
Priority to JP2017182377A priority patent/JP6496376B2/ja
Priority to AU2017268488A priority patent/AU2017268488B2/en
Priority to CY20171101358T priority patent/CY1119714T1/el
Priority to US15/864,499 priority patent/US10479788B2/en
Priority to US16/598,717 priority patent/US11046688B2/en
Priority to US17/319,231 priority patent/US11897877B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1216017.2A 2012-09-07 2012-09-07 Inhibitor compounds Ceased GB201216017D0 (en)

Priority Applications (33)

Application Number Priority Date Filing Date Title
GBGB1216017.2A GB201216017D0 (en) 2012-09-07 2012-09-07 Inhibitor compounds
PL13760106T PL2892889T3 (pl) 2012-09-07 2013-09-09 Związki inhibitorowe
DK17192253.7T DK3293183T3 (da) 2012-09-07 2013-09-09 Hæmmerforbindelser
RU2015112580A RU2673079C2 (ru) 2012-09-07 2013-09-09 Ингибиторные соединения
ES17192253T ES2742442T3 (es) 2012-09-07 2013-09-09 Compuestos inhibidores
NO13760106A NO2892889T3 (OSRAM) 2012-09-07 2013-09-09
EP13760106.8A EP2892889B1 (en) 2012-09-07 2013-09-09 Inhibitor compounds
JP2015530495A JP6216791B2 (ja) 2012-09-07 2013-09-09 阻害剤化合物
HK15112642.0A HK1211921B (en) 2012-09-07 2013-09-09 Inhibitor compounds
PCT/GB2013/052360 WO2014037750A1 (en) 2012-09-07 2013-09-09 Inhibitor compounds
PT137601068T PT2892889T (pt) 2012-09-07 2013-09-09 Compostos inibidores
HUE13760106A HUE036259T2 (hu) 2012-09-07 2013-09-09 Inhibitor vegyületek
ES13760106.8T ES2655194T3 (es) 2012-09-07 2013-09-09 Compuestos inhibidores
CN201380057967.7A CN104837829B (zh) 2012-09-07 2013-09-09 抑制剂化合物
SI201330829T SI2892889T1 (sl) 2012-09-07 2013-09-09 Inhibitorske spojine
SM20170596T SMT201700596T1 (it) 2012-09-07 2013-09-09 Composti inibitori
DK13760106.8T DK2892889T3 (en) 2012-09-07 2013-09-09 LIMITING RELATIONS
BR112015004489-1A BR112015004489B1 (pt) 2012-09-07 2013-09-09 Composto, composição farmacêutica, e, uso de um composto
CA2884006A CA2884006C (en) 2012-09-07 2013-09-09 Inhibitor compounds
US14/426,549 US9409907B2 (en) 2012-09-07 2013-09-09 Inhibitor compounds
RS20171314A RS56750B1 (sr) 2012-09-07 2013-09-09 Inhibitorna jedinjenja
AU2013311434A AU2013311434B2 (en) 2012-09-07 2013-09-09 Inhibitor compounds
HRP20171835TT HRP20171835T1 (hr) 2012-09-07 2013-09-09 Inhibitorni spojevi
LTEP13760106.8T LT2892889T (lt) 2012-09-07 2013-09-09 Inhibitoriaus junginiai
EP17192253.7A EP3293183B1 (en) 2012-09-07 2013-09-09 Inhibitor compounds
US15/091,887 US9890157B2 (en) 2012-09-07 2016-04-06 Inhibitor compounds
US15/091,980 US9834552B2 (en) 2012-09-07 2016-04-06 Inhibitor compounds
JP2017182377A JP6496376B2 (ja) 2012-09-07 2017-09-22 阻害剤化合物
AU2017268488A AU2017268488B2 (en) 2012-09-07 2017-11-27 Inhibitor compounds
CY20171101358T CY1119714T1 (el) 2012-09-07 2017-12-29 Ενωσεις αναστολεων
US15/864,499 US10479788B2 (en) 2012-09-07 2018-01-08 Compounds that inhibit MPS1 kinase
US16/598,717 US11046688B2 (en) 2012-09-07 2019-10-10 Inhibitor compounds
US17/319,231 US11897877B2 (en) 2012-09-07 2021-05-13 Inhibitor compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1216017.2A GB201216017D0 (en) 2012-09-07 2012-09-07 Inhibitor compounds

Publications (1)

Publication Number Publication Date
GB201216017D0 true GB201216017D0 (en) 2012-10-24

Family

ID=47137117

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1216017.2A Ceased GB201216017D0 (en) 2012-09-07 2012-09-07 Inhibitor compounds

Country Status (22)

Country Link
US (6) US9409907B2 (OSRAM)
EP (2) EP3293183B1 (OSRAM)
JP (2) JP6216791B2 (OSRAM)
CN (1) CN104837829B (OSRAM)
AU (2) AU2013311434B2 (OSRAM)
BR (1) BR112015004489B1 (OSRAM)
CA (1) CA2884006C (OSRAM)
CY (1) CY1119714T1 (OSRAM)
DK (2) DK2892889T3 (OSRAM)
ES (2) ES2742442T3 (OSRAM)
GB (1) GB201216017D0 (OSRAM)
HR (1) HRP20171835T1 (OSRAM)
HU (1) HUE036259T2 (OSRAM)
LT (1) LT2892889T (OSRAM)
NO (1) NO2892889T3 (OSRAM)
PL (1) PL2892889T3 (OSRAM)
PT (1) PT2892889T (OSRAM)
RS (1) RS56750B1 (OSRAM)
RU (1) RU2673079C2 (OSRAM)
SI (1) SI2892889T1 (OSRAM)
SM (1) SMT201700596T1 (OSRAM)
WO (1) WO2014037750A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
EP3231804B1 (en) 2008-03-21 2021-03-03 The General Hospital Corporation Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US20170050936A1 (en) * 2013-08-23 2017-02-23 Neupharma, Inc. Certain chemical entities, compositions, and methods
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6616934B2 (ja) * 2014-05-22 2019-12-04 株式会社 資生堂 レナリドミドの光学分割方法
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
DK3283642T3 (da) 2015-04-17 2024-01-02 Crossfire Oncology Holding B V Prognostiske biomarkører til ttk-hæmmerbaseret kemoterapi
HRP20211360T1 (hr) * 2015-05-29 2021-11-26 Teijin Pharma Limited Derivat pirido[3,4-d]pirimidina i njegova farmaceutski prihvatljiva sol
KR102591886B1 (ko) * 2015-07-21 2023-10-20 광저우 맥시노벨 파마수티컬스 씨오., 엘티디. 축합고리 피리미딘계 화합물, 중간체, 이의 제조 방법, 조성물 및 응용
GB201522532D0 (en) * 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CA3041854C (en) 2016-11-28 2025-05-13 Teijin Pharma Limited PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
DK3546458T3 (da) 2016-11-28 2021-02-22 Teijin Pharma Ltd ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidin- og ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidinderivater som cdk4/6-inhibitorer til behandling af for eksempel rheumatoid artritis, arteriosklerose, lungefibrose, cerebral infarkt eller kræft
WO2018234778A1 (en) * 2017-06-20 2018-12-27 The Institute Of Cancer Research: Royal Cancer Hospital METHODS AND MEDICAL USES
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
EP3701304B1 (en) 2017-10-26 2022-05-04 CommScope Connectivity Belgium BVBA Telecommunications system
GB201809460D0 (en) * 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
GB201809458D0 (en) 2018-06-08 2018-07-25 Crt Pioneer Fund Lp Salt form
KR102894761B1 (ko) 2019-10-30 2025-12-02 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 치환된 헤테로환형 융합된 환형 화합물, 이의 제조 방법 및 이의 약학적 용도
JP2023510918A (ja) * 2020-01-15 2023-03-15 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
KR102396930B1 (ko) * 2020-01-15 2022-05-12 한국과학기술연구원 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
EP4185566A4 (en) * 2020-07-16 2024-12-04 Dermavant Sciences GmbH ISOQUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF AHR IMBALANCE
CN115942937B (zh) * 2020-08-17 2025-07-25 浙江扬厉医药技术有限公司 嘧啶并环类化合物
AU2021381949A1 (en) 2020-11-18 2023-06-15 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CN115583946A (zh) * 2021-07-06 2023-01-10 赛诺哈勃药业（成都）有限公司 杂环化合物及其作为cdk抑制剂的用途
CN116354957A (zh) * 2021-12-16 2023-06-30 药捷安康(南京)科技股份有限公司 Cdk9抑制剂及其用途
WO2024238574A1 (en) * 2023-05-15 2024-11-21 Aleksia Therapeutics, Inc. Cdk inhibitor compounds
WO2025038785A1 (en) * 2023-08-16 2025-02-20 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications
CN117800875B (zh) * 2023-12-21 2024-10-22 泰州精英化成医药科技有限公司 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法
WO2025155740A1 (en) * 2024-01-17 2025-07-24 Iambic Therapeutics, Inc. Combinations comprising aza-quinazoline compounds for use in the treatment of cancer

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2697710A (en) 1953-01-02 1954-12-21 Burroughs Wellcome Co Pyrido (2,3-d) pyrimidines and method of preparing same
US3021332A (en) 1954-01-04 1962-02-13 Burroughs Wellcome Co Pyrido (2, 3-d) pyrimidine compounds and method of making
ES2146782T3 (es) 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
US7053070B2 (en) 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
MXPA02007221A (es) 2000-01-25 2002-11-29 Warner Lambert Co Inhibidores de pirido [2,3-d)pirimidin-2,7-diamina cinasa.
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
WO2002090360A1 (en) 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2003000011A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
JP2005516927A (ja) 2001-12-13 2005-06-09 アボット・ラボラトリーズ 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
BR0308232A (pt) 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas
RU2324695C2 (ru) * 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
US20040092521A1 (en) 2002-11-12 2004-05-13 Altenbach Robert J. Bicyclic-substituted amines as histamine-3 receptor ligands
JP4820094B2 (ja) 2002-11-12 2011-11-24 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての２環式置換アミン
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
US20050256118A1 (en) 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2007000240A1 (en) 2005-06-28 2007-01-04 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
ES2378473T3 (es) * 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US7998978B2 (en) 2006-05-01 2011-08-16 Pfizer Inc. Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
US20100216767A1 (en) 2006-12-22 2010-08-26 Mina Aikawa Quinazolines for pdk1 inhibition
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
WO2009084695A1 (ja) * 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
US9334242B2 (en) 2008-06-16 2016-05-10 Gtx, Inc. Compounds for treatment of cancer
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
GB201011182D0 (en) 2010-07-02 2010-08-18 Wireless Fibre Systems Ltd Riser wireless communications system
JP5997143B2 (ja) * 2010-07-30 2016-09-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
ES2377610B1 (es) 2010-09-01 2013-02-05 Institut Químic de Sarriá CETS Fundació Privada Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos.
EP2630136A1 (en) 2010-10-21 2013-08-28 Universität des Saarlandes Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2817460A1 (en) 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
CN103339134B (zh) * 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9745191B2 (en) 2011-04-11 2017-08-29 Saudi Arabian Oil Company Auto thermal reforming (ATR) catalytic structures
DK2739153T3 (en) 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
EP2766352B1 (en) 2011-10-12 2018-06-06 University Health Network (UHN) Indazole compounds as kinase inhibitors and method of treating cancer with same
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP2961409A1 (en) 2013-02-26 2016-01-06 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
US9675586B2 (en) 2013-12-06 2017-06-13 Genentech, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3119908A4 (en) 2014-03-11 2018-02-21 The Council Of The Queensland Institute Of Medical Research Determining cancer aggressiveness, prognosis and responsiveness to treatment
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
WO2016073771A2 (en) 2014-11-06 2016-05-12 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors
GB201522532D0 (en) 2015-12-21 2016-02-03 Cancer Rec Tech Ltd Novel pyrrolo[3,2-c]pyridine-6-amino derivatives
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
WO2018234778A1 (en) 2017-06-20 2018-12-27 The Institute Of Cancer Research: Royal Cancer Hospital METHODS AND MEDICAL USES

Also Published As

Publication number Publication date
HUE036259T2 (hu) 2018-06-28
NO2892889T3 (OSRAM) 2018-03-17
US10479788B2 (en) 2019-11-19
US9409907B2 (en) 2016-08-09
EP2892889A1 (en) 2015-07-15
US11046688B2 (en) 2021-06-29
CA2884006C (en) 2021-01-19
JP2018027967A (ja) 2018-02-22
EP3293183A1 (en) 2018-03-14
US20220402912A1 (en) 2022-12-22
ES2655194T3 (es) 2018-02-19
DK2892889T3 (en) 2017-12-11
BR112015004489B1 (pt) 2020-09-29
ES2742442T3 (es) 2020-02-14
US20150239884A1 (en) 2015-08-27
DK3293183T3 (da) 2019-08-12
JP2015527387A (ja) 2015-09-17
WO2014037750A1 (en) 2014-03-13
US20200165241A1 (en) 2020-05-28
US20180141944A1 (en) 2018-05-24
BR112015004489A2 (pt) 2017-07-04
RU2015112580A (ru) 2016-10-27
LT2892889T (lt) 2017-12-11
JP6216791B2 (ja) 2017-10-18
US9890157B2 (en) 2018-02-13
US20160220570A1 (en) 2016-08-04
AU2013311434A1 (en) 2015-04-02
RU2673079C2 (ru) 2018-11-22
US20160222009A1 (en) 2016-08-04
EP2892889B1 (en) 2017-10-18
SMT201700596T1 (it) 2018-01-11
AU2017268488B2 (en) 2019-06-13
RS56750B1 (sr) 2018-03-30
SI2892889T1 (sl) 2017-12-29
CY1119714T1 (el) 2018-06-27
AU2017268488A1 (en) 2017-12-14
US9834552B2 (en) 2017-12-05
JP6496376B2 (ja) 2019-04-03
US11897877B2 (en) 2024-02-13
HRP20171835T1 (hr) 2017-12-29
CN104837829B (zh) 2019-07-05
AU2013311434B2 (en) 2017-10-19
CA2884006A1 (en) 2014-03-13
CN104837829A (zh) 2015-08-12
EP3293183B1 (en) 2019-07-24
HK1211921A1 (en) 2016-06-03
PT2892889T (pt) 2018-01-09
PL2892889T3 (pl) 2018-03-30

Similar Documents

Publication Publication Date Title
IL268013A (en) Tetrahydropyrazolopyrimidine compounds
SI2892889T1 (sl) Inhibitorske spojine
EP2804479A4 (en) METALLOENZYME INHIBITOR COMPOUNDS
AP2014007810A0 (en) Imidazopyrrolidinone compounds
IL237341A0 (en) Compounds that promote neurogenesis
GB201209138D0 (en) Compounds
GB201214750D0 (en) Compounds
GB201215357D0 (en) Compounds
EP2894981A4 (en) METALLO ENZYME INHIBITOR COMPOUNDS
PL2804858T3 (pl) Związki - inhibitory metaloenzymu
EP2828262A4 (en) IMIDAZOTRIAZINONVERBINDUNGEN
GB201204985D0 (en) Compounds
GB201204125D0 (en) Compounds
PL2836495T3 (pl) Związki tetrahydropirolotiazynowe
GB201209096D0 (en) Compounds
IL235919A0 (en) inhibitors of fbxo3
GB201219820D0 (en) Compounds
GB201211019D0 (en) Inhibitor compounds
GB201217310D0 (en) Compounds
TWI561515B (en) Metalloenzyme inhibitor compounds
GB201223429D0 (en) Compounds
GB201220029D0 (en) Compounds
GB201219819D0 (en) Compounds
GB201218799D0 (en) Compounds
GB201218758D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)